India is widely recognized as a global pharmaceutical manufacturing hub. To understand the scale of this operation, one only needs to look at export data for Financial Year 2026 (FY26). India’s total pharmaceutical exports reached an impressive $31.1 billion. Out of this, the United States alone accounted for $9.47 billion, representing roughly 30.4% of the total export market. Simply put, the US remains an indispensable destination for Indian drugmakers.

Recently, market concerns emerged when the United States announced a steep 100% import duty (ad-valorem tariff) on patented pharmaceutical products and associated ingredients under Section 232 of the Trade Expansion Act. Such a heavy duty threatened to disrupt global supply chains, inflate healthcare costs, and erode profit margins for companies exporting specialized drugs to the US.

However, a major regulatory update on September 29, 2026, shifted momentum back in favor of the sector.

The Zero-Tariff Relief

The US Department of Commerce released an official notice outlining a tariff exemption for a select group of specialized pharmaceutical and medical products. India was included in a list of 20 partner jurisdictions, alongside countries such as Japan, South Korea, Switzerland, and the United Kingdom, whose qualifying products will benefit from this zero-duty treatment.

It is important to note that generic drugs remain exempt from Section 232 tariffs. Furthermore, this new waiver is product-specific rather than a blanket exemption for all patented exports. The 0% tariff category strictly applies to:

  • Orphan Drugs: Medicines used to treat rare diseases.
  • Fertility Treatments: Infertility medications and reproductive care therapies.
  • Advanced Therapies: Cell and gene therapies.
  • Targeted Biologics: Antibody-drug conjugates (ADCs).
  • Nuclear & Plasma Drugs: Nuclear medicines and plasma-derived therapies.
  • Animal Health: Veterinary and animal pharmaceutical products.
  • Manufacturing Inputs: Active pharmaceutical ingredients (APIs) and components used to produce these specific items.

Market Reaction

The announcement brought immediate relief to Indian drugmakers operating in these specialized segments. On September 29, 2026, pharmaceutical equities staged a sharp rally. The sectoral benchmark, the Nifty Pharma Index, surged over 1% to hit an intraday high of 27,032.40 points.

Key heavyweights and mid-cap stock movers included:

Sectoral Outperformance in 2026

This policy update highlights the structural resilience of the Indian pharmaceutical sector throughout 2026. While the broader equity market has faced macroeconomic headwinds—with the benchmark BSE Sensex down roughly 13% YTD, the Nifty Pharma index has gained approximately 18% over the same period.

Securing zero-tariff access for high-value, complex treatments ensures that Indian pharmaceutical leaders maintain their competitive cost edge and protect operational margins in their largest export destination.